Loading stock data…
€43.56+0.76 (+1.78%)
Fresenius SE & Co.
FRE.DE in the Healthcare sector is trading at €43.56. Wall Street consensus targets €55.59 (14 analysts), implying a +27.6% move over the next 12 months. The stock is currently 18% below its 52-week high of €52.96, remaining 0.4% below its 200-day moving average. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (EUR) | Q1 2025 | Q2 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | €5.71B↑ | €5.65B↓ | €6.16B↑ | €5.82B↓ | €5.95B |
| Gross Profit | €1.41B↓ | €1.46B↓ | €1.52B↓ | €1.53B↓ | €1.55B |
| Operating Income | €689.00M↑ | €562.00M↑ | €468.40M↓ | €601.00M↓ | €632.00M |
| Net Income | €229.00M↓ | €330.00M↓ | €361.00M↓ | €435.00M↑ | €382.00M |
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The F...